Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing

被引：2
|
作者：
Blay, J. Y. [1 ]
George, S. [2 ]
Casali, P. G. [3 ]
Le Cesne, A. [4 ]
Morgan, J. A. [2 ]
Pokela, J. [2 ]
Quigley, M. T. [2 ]
Tasse, V. [5 ]
Baum, C. M. [5 ]
Demetri, G. D. [2 ]
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Dana Faber Canc Inst, Boston, MA USA
[3] Inst Nazl Tumori, Milan, Italy
[4] Inst Gustave Roussy, Villejuif, France
[5] Pfizer Res & Dev, La Jolla, CA USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71478-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7501
引用
收藏
页码：402 / 402
页数：1
相关论文
共 50 条
  • [21] Efficacy, safety, pharmacokinetic and pharmacodynamic analysis of sunitinib adminstered on a continuous daily dosing schedule in patients with advanced gastrointestinal stromal tumor
    Blay, J.
    George, S.
    Casall, P.
    Le Cesne, A.
    Deprimo, S.
    Harmon, G.
    Law, C.
    Tassel, V
    Baum, C.
    Demetri, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 12 - 13
  • [22] Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
    Lankheet, N. A. G.
    Kloth, J. S. L.
    Gadellaa-van Hooijdonk, C. G. M.
    Cirkel, G. A.
    Mathijssen, R. H. J.
    Lolkema, M. P. J. K.
    Schellens, J. H. M.
    Voest, E. E.
    Sleijfer, S.
    de Jonge, M. J. A.
    Haanen, J. B. A. G.
    Beijnen, J. H.
    Huitema, A. D. R.
    Steeghs, N.
    BRITISH JOURNAL OF CANCER, 2014, 110 (10) : 2441 - 2449
  • [23] Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
    N A G Lankheet
    J S L Kloth
    C G M Gadellaa-van Hooijdonk
    G A Cirkel
    R H J Mathijssen
    M P J K Lolkema
    J H M Schellens
    E E Voest
    S Sleijfer
    M J A de Jonge
    J B A G Haanen
    J H Beijnen
    A D R Huitema
    N Steeghs
    British Journal of Cancer, 2014, 110 : 2441 - 2449
  • [24] Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial
    Cella, David
    Jensen, Sally E.
    Hahn, Elizabeth A.
    Beaumont, Jennifer L.
    Korytowsky, Beata
    Bhattacharyya, Helen
    Motzer, Robert
    CANCER MEDICINE, 2014, 3 (05): : 1353 - 1358
  • [25] A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio V.
    Novello, Silvia
    Brahamer, Julie R.
    Govindan, Ramaswamy
    Rosell, Rafael
    Belani, Chandra P.
    Atkins, James N.
    Tye, Lesley
    Chao, Richard
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S470 - S470
  • [26] Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
    Ordu, Cetin
    Pilanci, Kezban N.
    Avci, Nilufer
    Yildiz, Ibrahim
    Alco, Gul
    Demirhan, Ozkan
    Koksal, Ulkuhan I.
    Elbuken, Filiz
    Tecimer, Coskun
    Demir, Gokhan
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2016, 20 (02): : 147 - 152
  • [27] A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).
    George, S.
    von Mehren, M.
    Heinrich, M. C.
    Wang, Q.
    Corless, C. L.
    Butrynski, J. E.
    Morgan, J. A.
    Wagner, A. J.
    Choy, E.
    Tap, W. D.
    Manola, J.
    Yap, J. T.
    Van den Abbeele, A. D.
    Solomon, S.
    Fletcher, J. A.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG-PET
    Van den Abbeele, A. D.
    Yap, J. T.
    Rastarhuyeva, I.
    Akhurst, T.
    Keohan, M. L.
    George, S.
    Bhuchar, G.
    Morgan, J. A.
    Demetri, G. D.
    Maki, R. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Phase I/II study of sunitinib (SU) in combination with metronomic dosing of cyclophosphamide (C) and methotrexate (M) in patients (pts) with metastatic breast cancer (MBC)
    Chien, A. J.
    Aicardi, J.
    Melisko, M. E.
    Goga, A.
    Moasser, M. M.
    Park, J. W.
    Munster, P. N.
    Rugo, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Sunitinib continuous daily dosing in patients with cytokine-refractory metastatic renal cell carcinoma: Final results of a phase II study
    Roigas, J.
    Peschel, C.
    Escudier, B.
    ONKOLOGIE, 2008, 31 : 179 - 180
12345